cyclophosphamide + capecitabine + methotrexate + celecoxib + pamidronate

This combination regimen consists of five active pharmaceutical ingredients: **cyclophosphamide** (an alkylating agent and cytotoxic chemotherapy), **capecitabine** (an oral prodrug of 5-fluorouracil, acting as an antimetabolite), **methotrexate** (a folate antagonist antimetabolite and immunosuppressant), **celecoxib** (a selective cyclooxygenase-2 [COX-2] inhibitor NSAID), and **pamidronate** (a nitrogen-containing bisphosphonate for inhibition of bone resorption). The combination does not correspond to any known approved fixed-dose formulation or standard named protocol and is not referenced in current combination trials. Each component targets a distinct mechanism relevant to oncology supportive care and cytotoxic therapy: cyclophosphamide and capecitabine act synergistically as cytotoxic agents, methotrexate adds antiproliferative and immunosuppressive effects, celecoxib offers anti-inflammatory and potential antitumor effects via COX-2 inhibition, and pamidronate provides supportive care for bone metastases by inhibiting osteoclast-mediated bone resorption. All drugs are small molecules. This regimen would most likely be investigated in oncology settings, particularly for metastatic cancers with bone involvement; however, no direct evidence exists for clinical use or approval of all five agents together in a single regimen.

Other names

cyclophosphamide-HaEmek Medical Center, Israel-breast cancer (metastatic)Metronomic chemotherapy regimen (HaEmek)LDM chemotherapy + celecoxib + bisphosphonates